We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Alexion Pharmaceuticals Inc. (ALXN) said the U.S. Food and Drug Administration approved Soliris for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.
About three quarters of all patients with NMOSD test positive for anti-AQP4 auto-antibodies, Alexion said.
The FDA approved Soliris following an expedited six-month priority review. NMOSD is a rare, severe autoimmune disease that attacks the central nervous system without warning. These attacks can cause progressive and irreversible damage to the brain, optic nerve and spinal cord, the company said.
In a Phase 3 trial, at 48 weeks 98% of patients treated with Soliris were relapse free compared to 63% of patients receiving placebo, Alexion said.
Shares of Alexion were up 0.95% to $126.53 in Thursday afternoon trading.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 27, 2019 14:49 ET (18:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
